In melanoma, familial mutations in CDKN2A, RB1, and TERT attenuate senescence, enabling uncontrolled proliferation [309], whereas ERK5 inhibition triggers senescence via LTBP1-mediated TGF-β1 activation, which suppresses tumor growth and enhances immunotherapy response [310]. The gene discussed is RB1; the disease is neoplasm.